The thesis
Channel-pullback is a mean-reversion overlay on trend. It buys pullbacks to the lower regression channel or volume support within confirmed uptrends, then exits at the upper channel or resistance. In principle this is a sound, well-worn edge: you are not fading the trend, you are buying dips inside it. The universe is 24 large-cap US names spanning tech, financials, healthcare, staples, and energy — a diversified, liquid pool that suits a systematic dip-buyer.
Recent activity
The strategy is live and trading daily on a schedule, typically executing one order per run. Over the last week it has been almost entirely a BAC story: a full round-trip buy at $62.98 (Aug 6) into a sell at $63.12, then a fresh 31-share buy at $64.07 (Aug 13), a sell at $64.52 (Aug 14), and another buy at $64.24 (Aug 17). A pair of CAT trades and earlier AAPL and PG buys round out the tape. These are textbook small, quick pullback-to-bounce cycles — consistent with the thesis.
The live paper account has hovered just under $9,800 (recent totals between $9,711 and $9,847), so real-money-equivalent performance has been roughly flat-to-slightly-soft, a notably cooler read than the backtest.
Backtest and validation
On paper the numbers look inviting: +7.62% total return over 451 days, a $10,761 final equity, and a 4.19% CAGR. But the quality metrics temper the enthusiasm. The Sharpe is just 0.40, max drawdown reached 14.83%, and the win rate is only 39.39% across 137 trades — this is a strategy that wins by letting a minority of trades run, not by being frequently right. Turnover of 2,311% is high, so fees and slippage matter.
The walk-forward gate is where it breaks. Validation failed. Three of four folds were positive, but fold 2 (Jan–Jul 2025) lost 11.42% with a −1.70 Sharpe and a 16% drawdown, while fold 3 flattered the whole with a +20.68% burst. Out-of-sample return was a thinner 3.63%. Most damning, the deflated Sharpe (DSR) is 0.196 — after adjusting for 7 trials, the edge is statistically weak, even though the raw PSR (0.702) looks fine.
Verdict
The logic is coherent and the live trades match the doctrine, which is reassuring. But the honest read is a strategy whose apparent edge leans heavily on one strong window, with a low win rate and a failed validation gate warning of overfitting. Strengths: diversified universe, disciplined execution, positive full-sample return. Risks: fragile fold-to-fold consistency, high turnover, and a deflated Sharpe near zero. I would keep it live for observation, not scale it, until out-of-sample results stabilise.